EyePoint Pharmaceuticals, Inc. (EYPT)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 12.94 |
| Open | 12.90 |
| Bid | 12.49 x 600 |
| Ask | 12.55 x 600 |
| Day's range | 12.27 - 13.04 |
| 52-week range | 5.67 - 30.99 |
| Volume | |
| Avg. volume | 1,188,290 |
| Market cap | 652.097M |
| Beta (5Y monthly) | 1.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.81 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.44 |
GuruFocus.comInsider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
On May 14, 2024, David Guyer, Director at EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), executed a sale of 11,625 shares of the company.
GlobeNewswireEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an a
GuruFocus.comEyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges
Comprehensive Analysis of Financial Performance and Strategic Developments
© 2024 Yahoo. All rights reserved.